AVIR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
34.0M
-3.1%
35.1M
-26.9%
48.0M
-12.6%
54.9M
+20.6%
45.6M
R&D
27.1M
-3.8%
28.1M
-31.6%
41.1M
-14.0%
47.8M
+24.7%
38.3M
SG&A
6.9M
-0.4%
6.9M
+1.1%
6.9M
-3.4%
7.1M
-1.4%
7.2M
Operating Income
-34013000
+3.1%
-35099000
+26.9%
-48008000
+12.6%
-54934000
-20.6%
-45567000
EBITDA
-33909000
+3.1%
-34995000
+26.9%
-47904000
+12.6%
-54830000
-20.6%
-45463000
Net Income
-32162000
+2.3%
-32933000
+27.5%
-45440000
-1.3%
-44867000
-6.7%
-42049000
EPS (Basic)
$-0.40
+2.4%
$-0.41
+28.1%
$-0.57
+1.7%
$-0.58
-9.4%
$-0.53
EPS (Diluted)
$-0.40
+2.4%
$-0.41
+28.1%
$-0.57
+1.7%
$-0.58
-9.4%
$-0.53
Shares (Diluted)
80.2M
+0.2%
80.1M
+1.1%
79.2M
+1.5%
78.0M
-1.3%
79.1M
Atea Pharmaceuticals (AVIR) — Financials